The invention discloses a c-Met regulatory composition and its method for treating liver disease, a main component of the c-Met regulatory composition comprises Antrodin A and/or DMB (4,7-Dimethoxy-5-methyl-1,3-benzodioxole) capable of effectively regulating gene expression related to cell regeneration and cytothesis in hepatic cells, such as c-Met, Notch, etc., to achieve efficacies of repairing damaged hepatic cells and promoting hepatocyte regeneration.

The invention discloses a c-Met regulatory composition and its method for treating liver disease, a main component of the c-Met regulatory composition comprises Antrodin A and/or DMB (4,7-Dimethoxy-5-methyl-1,3-benzodioxole) capable of effectively regulating gene expression related to cell regeneration and cytothesis in hepatic cells, such as c-Met, Notch, etc., to achieve efficacies of repairing damaged hepatic cells and promoting hepatocyte regeneration.

Disclosed is use of a composition for preventing and/or eliminating platelet aggregation in an in vitro blood sample. The composition comprises at least one compound selected from the group consisting of formula, R1-NH—R2, and a salt thereof. Also disclosed is an agent, which comprises the compound for reducing platelet aggregation interference in an in vitro blood test, and a method for preventing and/or eliminating platelet aggregation in a sample in an in vitro blood test. The compound of the present invention exhibits a disaggregation effect in multiple types of platelet aggregation circumstances, and the platelet disaggregation takes effect within a short time without additional conditions such as temperature control with water bath, prolonged reaction time and the like, thereby eliminating platelet aggregation in a sample conveniently and thus accurate blood cell detection parameters can be obtained.

The present invention concerns a pharmaceutically acceptable salt of a compound of the following formula (I): H.sub.2N—CH(R.sub.1)—CH.sub.2S—S—CH.sub.2—CH(R.sub.2—CONH—CH(R.sub.3)—COOR.sub.4 (I) and more particularly an acid addition salt thereof, and the compositions comprising the same, for use in the prevention or treatment of trigeminal nerve pain, in particular migraines or trigeminal neuralgia.

The present invention concerns a pharmaceutically acceptable salt of a compound of the following formula (I): H.sub.2N—CH(R.sub.1)—CH.sub.2S—S—CH.sub.2—CH(R.sub.2—CONH—CH(R.sub.3)—COOR.sub.4 (I) and more particularly an acid addition salt thereof, and the compositions comprising the same, for use in the prevention or treatment of trigeminal nerve pain, in particular migraines or trigeminal neuralgia.

The present invention relates to a compound selected from the group consisting of of N-[(2S)-1-amino-3-(3-fluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)thiophene-2-carboxamide, [2-(2,6-dichloroanilino)-4,5-dihydroimidazol-1-yl]-phenylmethanone, 2-amino-5-bromo-4-phenyl-1H-pyrimidin-6-one, N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide and 2-(1,4-dioxaspiro[4.5]decan-2-ylmethyl)guanidin, or a pharmaceutically acceptable salt thereof and combinations comprising at least one of said compounds, for use in the treatment and/or prevention of synucleinopathies.

The present invention relates to a compound selected from the group consisting of of N-[(2S)-1-amino-3-(3-fluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)thiophene-2-carboxamide, [2-(2,6-dichloroanilino)-4,5-dihydroimidazol-1-yl]-phenylmethanone, 2-amino-5-bromo-4-phenyl-1H-pyrimidin-6-one, N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide and 2-(1,4-dioxaspiro[4.5]decan-2-ylmethyl)guanidin, or a pharmaceutically acceptable salt thereof and combinations comprising at least one of said compounds, for use in the treatment and/or prevention of synucleinopathies.

Methods, filters and compositions are disclosed for treating toxicity due to oxidative stress and toxic electrophiles.

Methods, filters and compositions are disclosed for treating toxicity due to oxidative stress and toxic electrophiles.

Methods, filters and compositions are disclosed for treating toxicity due to oxidative stress and toxic electrophiles.